Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection

키워드

참고문헌 (57)

1. Cohen A, "The global prevalence of latent tuberculosis : a systematic review and meta-analysis", Eur Respir J, 54, pp.54~ (2019)
2. Global Tuberculosis Report 2021, "World Health Organization", World Health Organization, ~ (2021)
3. Larsen SE, "It takes a village : the multifaceted immune response to Mycobacterium tuberculosis infection and vaccine-induced immunity", Front Immunol, 13, pp.840225~ (2022)
4. Mangtani P, "Protection by BCG vaccine against tuberculosis : a systematic review of randomized controlled trials", Clin Infect Dis, 58, pp.470~480 (2014)
5. Trunz BB, "Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide : a meta-analysis and assessment of cost-effectiveness", Lancet, 367, pp.1173~1180 (2006)
6. Nemes E, "Prevention of M. tuberculosis infection with H4 : IC31 vaccine or BCG revaccination", N Engl J Med, 379, pp.138~149 (2018)
7. Van Der Meeren O, "Phase 2b controlled trial of M72", AS01E vaccine to prevent tuberculosis, 2018, pp.379, 1621~1634
8. Billeskov R, "The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity", PLoS One, 7, pp.e39909~ (2012)
9. Reed SG, "Defined tuberculosis vaccine, Mtb72F", AS02A, evidence of protection in cynomolgus monkeys, 2009, pp.106, 2301~2306
10. Ullah N, "Differential immunogenicity and protective efficacy elicited by MTO-and DMT-adjuvanted CMFO subunit vaccines against Mycobacterium tuberculosis infection", J Immunol Res, 2020, pp.2083793~ (2020)
11. Reed SG, "Key roles of adjuvants in modern vaccines", Nat Med, 19, pp.1597~1608 (2013)
12. Orr MT, "Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis", J Control Release, 172, pp.190~200 (2013)
13. Moreno-Mendieta SA, "Adjuvants in tuberculosis vaccine development", FEMS Immunol Med Microbiol, 58, pp.75~84 (2010)
14. Agger EM, "Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates", Adv Drug Deliv Rev, 102, pp.73~82 (2016)
15. Leroux-Roels I, "Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72", AS01 as compared to the M72, AS02 tuberculosis candidate vaccine formulations : a randomized trial, pp.Vaccine, 2013[DOI]
16. Kim SJ, "Transmission of Mycobacterium tuberculosis among high school students in Korea", Int J Tuberc Lung Dis, 5, pp.824~830 (2001)
17. Kim WS, "Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosis", Sci Rep, 8, pp.14411~ (2018)
18. Kim WS, "Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain", Oncotarget, 7, pp.24962~24982 (2016)
19. Pedersen GK, "Immunocorrelates of CAF family adjuvants", Semin Immunol, 39, pp.4~13 (2018)
20. Andersen P, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins", Infect Immun, 62, pp.2536~2544 (1994)
21. Kwon KW, "Long-term protective efficacy with a BCG-prime ID93", GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model, 2019, pp.9, 15560~
22. Jeon BY, "The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis", Microbes Infect, 13, pp.284~290 (2011)
23. Kang TG, "Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx", Nat Commun, 13, pp.3155~ (2022)
24. Darrah PA, "Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major", Nat Med, 13, pp.843~850 (2007)
25. Rosenbaum P, "Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response", Front Immunol, 12, pp.645210~ (2021)
26. Tait DR, "Final analysis of a trial of M72", AS01E vaccine to prevent tuberculosis, 2019, pp.381, 2429~2439
27. Ganguly N, "Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence", Tuberculosis(Edinb), 88, pp.510~517 (2008)
28. Coppola M, "Cell-mediated immune responses to in vivo-expressed and stage-specific Mycobacterium tuberculosis antigens in latent and active tuberculosis across different age groups", Front Immunol, 11, pp.103~ (2020)
29. Penn-Nicholson A, "Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa : a randomised, double-blind, placebo-controlled phase 1 trial", Lancet Respir Med, 6, pp.287~298 (2018)
30. Shekhawat SD, "Evaluation of heat shock proteins for discriminating between latent tuberculosis infection and active tuberculosis : a preliminary report", J Infect Public Health, 9, pp.143~152 (2016)
31. Wilkinson KA, "Infection biology of a novel alpha-crystallin of Mycobacterium tuberculosis : Acr2", J Immunol, 174, pp.4237~4243 (2005)
32. Sassetti CM, "Genetic requirements for mycobacterial survival during infection", Proc Natl Acad Sci U S A, 100, pp.12989~12994 (2003)
33. Triccas JA, "Analysis of stress-and host cell-induced expression of the Mycobacterium tuberculosis inorganic pyrophosphatase", BMC Microbiol, 1, pp.3~ (2001)
34. Griffin JE, "High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism", PLoS Pathog, 7, pp.e1002251~ (2011)
35. Stewart E, "Adjuvant strategies for more effective tuberculosis vaccine immunity", Microorganisms, 7, pp.255~ (2019)
36. Patin EC, "Macrophage inducible C-type lectin as a multifunctional player in immunity", Front Immunol, 8, pp.861~ (2017)
37. Desel C, "The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling", PLoS One, 8, pp.e53531~ (2013)
38. Martins KA, "Vaccine adjuvant uses of poly-IC and derivatives", Expert Rev Vaccines, 14, pp.447~459 (2015)
39. Marty-Roix R, "Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants", J Biol Chem, 291, pp.1123~1136 (2016)
40. Enriquez AB, "Advancing adjuvants for Mycobacterium tuberculosis therapeutics", Front Immunol, 12, pp.740117~ (2021)
41. Wu Z, "Overview of vaccine adjuvants", Medicine in Drug Discovery, 11, pp.100103~ (2021)
42. Uthayakumar D, "Non-specific effects of vaccines illustrated through the BCG example : from observations to demonstrations", Front Immunol, 9, pp.2869~ (2018)
43. Aaby P, "Randomized trial of BCG vaccination at birth to low-birth-weight children : beneficial nonspecific effects in the neonatal period?", J Infect Dis, 204, pp.245~252 (2011)
44. Soysal A, "Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact : a prospective community-based study", Lancet, 366, pp.1443~1451 (2005)
45. Eisenhut M, "BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay", Vaccine, 27, pp.6116~6120 (2009)
46. Roy A, "Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis", BMJ, 349, pp.g4643~ (2014)
47. Luabeya AK, "First-in-human trial of the post-exposure tuberculosis vaccine H56 : IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults", Vaccine, 33, pp.4130~4140 (2015)
48. Penn-Nicholson A, "Safety and immunogenicity of candidate vaccine M72", AS01E in adolescents in a TB endemic setting, 2015, pp.33, 4025~4034
49. Pollock KM, "PD-1 expression and cytokine secretion profiles of Mycobacterium tuberculosis-specific CD4+ T-cell subsets; potential correlates of containment in HIV-TB co-infection", PLoS One, 11, pp.e0146905~ (2016)
50. Mittrücker HW, "Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis", Proc Natl Acad Sci U S A, 104, pp.12434~12439 (2007)
51. Bertholet S, "A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis", Sci Transl Med, 2, pp.53~74 (2010)
52. Corey L, "Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection : two randomized controlled trials", JAMA, 282, pp.331~340 (1999)
53. Belshe RB, "Efficacy results of a trial of a herpes simplex vaccine", N Engl J Med, 366, pp.34~43 (2012)
54. Tan X, "Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge", J Virol, 85, pp.8316~8327 (2011)
55. Marchioro SB, "Local and systemic immune responses in pigs intramuscularly injected with an inactivated Mycoplasma hyopneumoniae vaccine", Vaccine, 31, pp.1305~1311 (2013)
56. Baldwin SL, "Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations", Front Microbiol, 13, pp.935444~ (2022)
57. Woodworth JS, "Mucosal boosting of H56 : CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection", Mucosal Immunol, 12, pp.816~826 (2019)

관련 논문AI추천